Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States

Gerald Naccarelli, Stephen S. Johnston, Jay Lin, Parag P. Patel, Kathy L. Schulman

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: The ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) demonstrated that dronedarone reduced the risk of cardiovascular (CV) hospitalization/death by 24% (P < 0.001) in patients with atrial fibrillation (AF) and atrial flutter (AFL). Hypothesis: In order to estimate the cost savings associated with dronedarone use, we estimated the costs associated with CV hospitalizations and in patient mortality in a large cohort of ATHENA-like patients. Methods: In this retrospective analysis, we evaluated the cost of CV hospitalization/mortality in real-world ATHENA-like patients without heart failure and with employer-sponsored Medicare supplemental insurance in the United States. Patients similar to those in ATHENA (age ≥70 years with AF/AFL and ≥1 stroke risk factor, without heart failure) who were hospitalized between January 2, 2005, and January 1, 2007, were identified from the MarketScan databases from Thomson Reuters. Health care costs were evaluated during the 12 months following the index hospitalization. Results: The analysis included 10 200 ATHENA-like patients. Hospitalization for CV causes occurred in 53.9% of patients, with a total of 6700 CV hospitalizations for fatal/nonfatal causes. Themost common nonfatal causes of CV hospitalizations were AF/other supraventricular rhythm disorders (20.2%of all CV hospitalizations), congestive heart failure (CHF; 14.3%), and transient ischemic attack (TIA)/stroke (10.7%).Mean costs per CV hospitalization for nonfatal causes were $10908. Inpatient deaths from CV causes occurred in 264(2.6%) patients; the most common causes of CV in patient death were intracranial/gastrointestinal hemorrhage (24.2% of CV deaths), TIA/stroke (17.0%), and CHF (15.9%).Mean hospitalization costsper CV in patient death were $18 565. Conclusions: Health care costs associated with CV hospitalizations and inpatient deaths among ATHENA-like patients in the US are high. Novel antiarrhythmic therapies such as dronedarone, with the potential to reduce CV hospitalizations/mortality in similar patients, could decrease health care costs if adopted in clinical practice.

Original languageEnglish (US)
Pages (from-to)270-279
Number of pages10
JournalClinical Cardiology
Volume33
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Atrial Flutter
Atrial Fibrillation
Hospitalization
Costs and Cost Analysis
Mortality
Health Care Costs
Heart Failure
Stroke
Transient Ischemic Attack
Inpatients
Cause of Death
Gastrointestinal Hemorrhage
Intracranial Hemorrhages
Cost Savings
Medicare
Insurance

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{331be79a4fc74880b785e4b1bcc4145b,
title = "Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States",
abstract = "Background: The ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) demonstrated that dronedarone reduced the risk of cardiovascular (CV) hospitalization/death by 24{\%} (P < 0.001) in patients with atrial fibrillation (AF) and atrial flutter (AFL). Hypothesis: In order to estimate the cost savings associated with dronedarone use, we estimated the costs associated with CV hospitalizations and in patient mortality in a large cohort of ATHENA-like patients. Methods: In this retrospective analysis, we evaluated the cost of CV hospitalization/mortality in real-world ATHENA-like patients without heart failure and with employer-sponsored Medicare supplemental insurance in the United States. Patients similar to those in ATHENA (age ≥70 years with AF/AFL and ≥1 stroke risk factor, without heart failure) who were hospitalized between January 2, 2005, and January 1, 2007, were identified from the MarketScan databases from Thomson Reuters. Health care costs were evaluated during the 12 months following the index hospitalization. Results: The analysis included 10 200 ATHENA-like patients. Hospitalization for CV causes occurred in 53.9{\%} of patients, with a total of 6700 CV hospitalizations for fatal/nonfatal causes. Themost common nonfatal causes of CV hospitalizations were AF/other supraventricular rhythm disorders (20.2{\%}of all CV hospitalizations), congestive heart failure (CHF; 14.3{\%}), and transient ischemic attack (TIA)/stroke (10.7{\%}).Mean costs per CV hospitalization for nonfatal causes were $10908. Inpatient deaths from CV causes occurred in 264(2.6{\%}) patients; the most common causes of CV in patient death were intracranial/gastrointestinal hemorrhage (24.2{\%} of CV deaths), TIA/stroke (17.0{\%}), and CHF (15.9{\%}).Mean hospitalization costsper CV in patient death were $18 565. Conclusions: Health care costs associated with CV hospitalizations and inpatient deaths among ATHENA-like patients in the US are high. Novel antiarrhythmic therapies such as dronedarone, with the potential to reduce CV hospitalizations/mortality in similar patients, could decrease health care costs if adopted in clinical practice.",
author = "Gerald Naccarelli and Johnston, {Stephen S.} and Jay Lin and Patel, {Parag P.} and Schulman, {Kathy L.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1002/clc.20759",
language = "English (US)",
volume = "33",
pages = "270--279",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. / Naccarelli, Gerald; Johnston, Stephen S.; Lin, Jay; Patel, Parag P.; Schulman, Kathy L.

In: Clinical Cardiology, Vol. 33, No. 5, 01.05.2010, p. 270-279.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States

AU - Naccarelli, Gerald

AU - Johnston, Stephen S.

AU - Lin, Jay

AU - Patel, Parag P.

AU - Schulman, Kathy L.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Background: The ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) demonstrated that dronedarone reduced the risk of cardiovascular (CV) hospitalization/death by 24% (P < 0.001) in patients with atrial fibrillation (AF) and atrial flutter (AFL). Hypothesis: In order to estimate the cost savings associated with dronedarone use, we estimated the costs associated with CV hospitalizations and in patient mortality in a large cohort of ATHENA-like patients. Methods: In this retrospective analysis, we evaluated the cost of CV hospitalization/mortality in real-world ATHENA-like patients without heart failure and with employer-sponsored Medicare supplemental insurance in the United States. Patients similar to those in ATHENA (age ≥70 years with AF/AFL and ≥1 stroke risk factor, without heart failure) who were hospitalized between January 2, 2005, and January 1, 2007, were identified from the MarketScan databases from Thomson Reuters. Health care costs were evaluated during the 12 months following the index hospitalization. Results: The analysis included 10 200 ATHENA-like patients. Hospitalization for CV causes occurred in 53.9% of patients, with a total of 6700 CV hospitalizations for fatal/nonfatal causes. Themost common nonfatal causes of CV hospitalizations were AF/other supraventricular rhythm disorders (20.2%of all CV hospitalizations), congestive heart failure (CHF; 14.3%), and transient ischemic attack (TIA)/stroke (10.7%).Mean costs per CV hospitalization for nonfatal causes were $10908. Inpatient deaths from CV causes occurred in 264(2.6%) patients; the most common causes of CV in patient death were intracranial/gastrointestinal hemorrhage (24.2% of CV deaths), TIA/stroke (17.0%), and CHF (15.9%).Mean hospitalization costsper CV in patient death were $18 565. Conclusions: Health care costs associated with CV hospitalizations and inpatient deaths among ATHENA-like patients in the US are high. Novel antiarrhythmic therapies such as dronedarone, with the potential to reduce CV hospitalizations/mortality in similar patients, could decrease health care costs if adopted in clinical practice.

AB - Background: The ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) demonstrated that dronedarone reduced the risk of cardiovascular (CV) hospitalization/death by 24% (P < 0.001) in patients with atrial fibrillation (AF) and atrial flutter (AFL). Hypothesis: In order to estimate the cost savings associated with dronedarone use, we estimated the costs associated with CV hospitalizations and in patient mortality in a large cohort of ATHENA-like patients. Methods: In this retrospective analysis, we evaluated the cost of CV hospitalization/mortality in real-world ATHENA-like patients without heart failure and with employer-sponsored Medicare supplemental insurance in the United States. Patients similar to those in ATHENA (age ≥70 years with AF/AFL and ≥1 stroke risk factor, without heart failure) who were hospitalized between January 2, 2005, and January 1, 2007, were identified from the MarketScan databases from Thomson Reuters. Health care costs were evaluated during the 12 months following the index hospitalization. Results: The analysis included 10 200 ATHENA-like patients. Hospitalization for CV causes occurred in 53.9% of patients, with a total of 6700 CV hospitalizations for fatal/nonfatal causes. Themost common nonfatal causes of CV hospitalizations were AF/other supraventricular rhythm disorders (20.2%of all CV hospitalizations), congestive heart failure (CHF; 14.3%), and transient ischemic attack (TIA)/stroke (10.7%).Mean costs per CV hospitalization for nonfatal causes were $10908. Inpatient deaths from CV causes occurred in 264(2.6%) patients; the most common causes of CV in patient death were intracranial/gastrointestinal hemorrhage (24.2% of CV deaths), TIA/stroke (17.0%), and CHF (15.9%).Mean hospitalization costsper CV in patient death were $18 565. Conclusions: Health care costs associated with CV hospitalizations and inpatient deaths among ATHENA-like patients in the US are high. Novel antiarrhythmic therapies such as dronedarone, with the potential to reduce CV hospitalizations/mortality in similar patients, could decrease health care costs if adopted in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=77953168894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953168894&partnerID=8YFLogxK

U2 - 10.1002/clc.20759

DO - 10.1002/clc.20759

M3 - Article

C2 - 20513065

AN - SCOPUS:77953168894

VL - 33

SP - 270

EP - 279

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 5

ER -